- Home
- DSU vs PHAR Comparison
DSU vs PHAR Comparison
Compare DSU & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSU
- PHAR
- Stock Information
- Founded
- DSU 1998
- PHAR 1988
- Country
- DSU United States
- PHAR Netherlands
- Employees
- DSU N/A
- PHAR N/A
- Industry
- DSU Finance Companies
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- DSU Finance
- PHAR Health Care
- Exchange
- DSU Nasdaq
- PHAR Nasdaq
- Market Cap
- DSU 519.1M
- PHAR 587.5M
- IPO Year
- DSU N/A
- PHAR N/A
- Fundamental
- Price
- DSU $9.91
- PHAR N/A
- Analyst Decision
- DSU
- PHAR Strong Buy
- Analyst Count
- DSU 0
- PHAR 3
- Target Price
- DSU N/A
- PHAR $30.00
- AVG Volume (30 Days)
- DSU 148.2K
- PHAR 4.6K
- Earning Date
- DSU 01-01-0001
- PHAR 05-08-2025
- Dividend Yield
- DSU 10.06%
- PHAR N/A
- EPS Growth
- DSU N/A
- PHAR N/A
- EPS
- DSU N/A
- PHAR N/A
- Revenue
- DSU N/A
- PHAR $297,200,000.00
- Revenue This Year
- DSU N/A
- PHAR $8.26
- Revenue Next Year
- DSU N/A
- PHAR $9.73
- P/E Ratio
- DSU N/A
- PHAR N/A
- Revenue Growth
- DSU N/A
- PHAR 21.15
- 52 Week Low
- DSU $9.22
- PHAR $6.65
- 52 Week High
- DSU $11.40
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- DSU 42.09
- PHAR 45.53
- Support Level
- DSU $8.72
- PHAR $7.79
- Resistance Level
- DSU $10.06
- PHAR $8.51
- Average True Range (ATR)
- DSU 0.26
- PHAR 0.47
- MACD
- DSU 0.01
- PHAR 0.01
- Stochastic Oscillator
- DSU 65.03
- PHAR 49.08
About DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.